Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Revenue | 256M | 823.7% |
| Operating expense | 212M | 13.5% |
| Net Income | -24M | 86.4% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 1.39B | 0.3% |
| Total Liabilities | 882M | 2.4% |
| Total Equity | 466M | 10.8% |
| Shares Outstanding | 136M | 2.4% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | 20M | 113.2% |
| Cash from financing | 3.7M | 108.6% |
EPS
Financial Highlights for Arrowhead Pharmaceuticals in Q3 '25
Arrowhead Pharmaceuticals reported a revenue of 256M, which is a 823.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Operating Expenses for this period were 212M, showing a 13.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -24M, showing a 86.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
Arrowhead Pharmaceuticals faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
